Fig. 1 · Structure

Documents & Downloads

MLN8054

Cat. No. A10601 CAS 869363-13-3

Aurora A Inhibitor

MLN8054 is an inhibitor of Aurora A kinase, induces senescence in human tumor cells both in vitro and in vivo.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
AuroraA IC50 4nM
AuroraB IC50 172nM
LCK IC50 3.2μM
PKA IC50 19μM
CK2 IC50 20.5μM
Chk2 IC50 28μM
PLK1 IC50 53μM
Chk1 IC50 >100μM
PKC IC50 >100μM
CaMKII IC50 >100μM
CDK2E IC50 >100μM
CDK1 IC50 >100μM

12 targets · Scroll to view more

Cellular Effect

Cell Line Activity Value Description Reference
Calu-6 IC50 0.22 μM Antiproliferative activity against human Calu6 cells after 96 hrs by BrdU cell proliferation ELISA [PMID: 17360485]
DLD-1 IC50 1.43 μM Antiproliferative activity against human DLD1 cells after 96 hrs by BrdU cell proliferation ELISA [PMID: 17360485]
HCT-116 IC50 0.1 μM Antiproliferative activity against human HCT116 cells after 4 days by celltiter assay [PMID: 19402633]
HCT-116 IC50 0.16 μM Inhibition of Aurora A in human HCT116 cells assessed as complete failure of centrosome seperation by immunofluorescence assay [PMID: 19402633]
HCT-116 IC50 0.18 μM Antiproliferative activity against human HCT116 cells after 96 hrs by BrdU cell proliferation ELISA [PMID: 17360485]
HCT-116 GI50 0.22 μM Cytotoxicity against human HCT116 cells assessed as inhibition of cell proliferation by BrdU incorporation assay [PMID: 26101564]
HCT-116 IC50 0.31 μM Inhibition of Aurora A in human HCT116 cells assessed as complete loss of phospho-Aurora A staining in centrosomes by immunofluorescence assay [PMID: 19402633]
HCT-116 IC50 0.69 μM Cytotoxicity against human HCT116 cells after 5 days by MTS assay [PMID: 22326168]
HCT-116 IC50 0.85 μM Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 48 hrs by MTT assay [PMID: 30143423]
HCT-116 IC50 34 nM Inhibition of aurora kinase A autophosphorylation at T288 in human HCT116 cells by immunofluorescence analysis [PMID: 26101564]
HCT-116 IC50 34 nM Inhibition of aurora A autophosphorylation in human HCT116 cells by immunofluorescence method [PMID: 19320489]
HCT-116 IC50 4 μM Inhibition of aurora B in human HCT116 cells assessed as inhibition of histone H3 Ser10 phosphorylation by immunofluorescence method [PMID: 19320489]
HCT-116 IC50 5 μM Inhibition of Aurora B in human HCT116 cells assessed as complete loss of phospho-histamine H3 staining by immunofluorescence assay [PMID: 19402633]
HCT-116 IC50 5.2 μM Inhibition of aurora kinase B in human HCT116 cells assessed as inhibition of histone H3 phosphorylation by immunofluorescence analysis [PMID: 26101564]
HeLa IC50 0.034 μM Inhibition of Aurora A Thr288 autophosphorylation in human HeLa cells after 1 hr [PMID: 17360485]
HeLa IC50 5.7 μM Inhibition of Aurora B Ser10 phosphorylation in human HeLa cells after 1 hr [PMID: 17360485]
HT-29 IC50 0.15 μM Antiproliferative activity against human HT-29 cells after 4 days by celltiter assay [PMID: 19402633]
MCF7 IC50 0.67 μM Antiproliferative activity against human MCF7 cells after 96 hrs by BrdU cell proliferation ELISA [PMID: 17360485]
MDA-MB-231 IC50 0.74 μM Antiproliferative activity against human MDAMB231 cells after 96 hrs by BrdU cell proliferation ELISA [PMID: 17360485]
NCI-H460 IC50 0.11 μM Antiproliferative activity against human H460 cells after 96 hrs by BrdU cell proliferation ELISA [PMID: 17360485]

20 records · Scroll to view more

MLN8054 Research Summary

This section summarizes 4 in vitro studies of MLN8054 from 3 published references. In vitro models include immobilized AURKA; bovine oocytes.

MLN8054 In Vitro Studies

Model: immobilized AURKA. Treatment: increasing concentrations. Result: Kd 2.28 ± 0.03 nM. Bovine oocytes were treated with the study compound in maturation medium for 23 h. Levels of phosphorylated TACC3 (pTACC3) decreased to 77% of the control levels. HeLa cells received inhibitor treatment at 0.5 µM during the final hour of washout, with each condition compared with its corresponding untreated control. Treatment reduced S69 phosphorylation to a greater extent than S55 phosphorylation and even more so than S44 phosphorylation. Model: purified kinase domain of AURKA. Treatment: 0.15 nM, 0.31 nM, 0.62 nM, 1.25 nM, 2.5 nM, 5 nM, 10 nM, 20 nM, 40 nM, 80 nM, and 160 nM. Result: IC50 = 6 nM. [1,2,3]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

equilibrium dissociation constant (Kd) in immobilized AURKA

Cell-based study · immobilized AURKA [1]

Model: immobilized AURKA. Treatment: increasing concentrations. Result: Kd 2.28 ± 0.03 nM.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
equilibrium dissociation constant (Kd)Kd 2.28 ± 0.03 nM[1]

Literature-Reported Treatment Conditions

Treatment concentration
increasing concentrations
Exposure duration
A dissociation of 180 s
Method
injected at different concentrations onto the sensor chip
Vehicle
10 mM Hepes pH 7.4, 150 mM NaCl, 1% DMSO, 0.005% Tween20
Methods and source locations

Compound reported in the paper: MLN8054

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

2. Results > 2.2. PHA-680626 and RPM1722 Behave as CD Inhibitors In Vitro (S16, S17); 4. Materials and Methods > 4.5. Surface Plasmon Resonance (S93, S95, S100, S102, S111); Figure 2 legend (S163); Table 2 (T2.h1, T2.r2)

equilibrium dissociation constant (Kd): equilibrium dissociation constant (Kd); comparator: Flow cell Ch2 was left empty and used as a control — 4. Materials and Methods > 4.5. Surface Plasmon Resonance (S111); Table 2 (T2.h1, T2.r2)

Reduced Phosphorylated TACC3 Levels in Bovine Oocytes

Cell-based study · bovine oocytes [2]

Bovine oocytes were treated with the study compound in maturation medium for 23 h. Levels of phosphorylated TACC3 (pTACC3) decreased to 77% of the control levels.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
levels of phosphorylated TACC3 (pTACC3)phosphorylated TACC3 levels 77% of the control levels[2]

Literature-Reported Treatment Conditions

Exposure duration
23 h
Method
in maturation medium
Vehicle
dimethyl sulfoxide (DMSO)
Reported limits
Not stated in the sentences used: dose.
Methods and source locations

Compound reported in the paper: MLN8054

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and Methods > Aurora A kinase inhibition (S50, S51); Results > Indirect inhibition of TACC3 using MLN8054 disrupts meiotic spindle formation in a dose-dependent manner (S101)

levels of phosphorylated TACC3 (pTACC3): levels of phosphorylated TACC3 (pTACC3); comparator: normal maturation medium, or maturation medium containing DMSO (0.02%) — Results > Indirect inhibition of TACC3 using MLN8054 disrupts meiotic spindle formation in a dose-dependent manner (S101)

Inhibitor treatment and phosphorylation in HeLa cells

Cell-based study · HeLa cells [3]

HeLa cells received inhibitor treatment at 0.5 µM during the final hour of washout, with each condition compared with its corresponding untreated control. Treatment reduced S69 phosphorylation to a greater extent than S55 phosphorylation and even more so than S44 phosphorylation.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
S69 phosphorylationReported result S69 phosphorylation was reduced to a greater extent after inhibitor treatment compared with S55 and even more so compared with S44[3]

Literature-Reported Treatment Conditions

Treatment concentration
0.5 µM
Exposure duration
treated in the final hour of washout (9–10 h after washout)
Co-treatment
Other interventions in this design: thymidine. Compound effect isolated by the comparison: each condition is compared with the corresponding untreated control.
Reported limits
Not stated in the sentences used: route, vehicle.
Methods and source locations

Compound reported in the paper: MLN8054

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results (S17); Materials and methods > Cell treatments and transfections (S110, S111); Materials and methods > Immunofluorescence (S117); Figure 3. legend (S236, S239); Figure 5. legend (S251, S257)

S69 phosphorylation: S69 phosphorylation; comparator: corresponding untreated control — Results (S17)

kinase activity of AURKA in purified kinase domain of AURKA

Biochemical assay · purified kinase domain of AURKA [1]

Model: purified kinase domain of AURKA. Treatment: 0.15 nM, 0.31 nM, 0.62 nM, 1.25 nM, 2.5 nM, 5 nM, 10 nM, 20 nM, 40 nM, 80 nM, and 160 nM. Result: IC50 = 6 nM.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
kinase activity of AURKAIC50 6 nM[1]

Literature-Reported Treatment Conditions

Treatment concentration
0.15 nM, 0.31 nM, 0.62 nM, 1.25 nM, 2.5 nM, 5 nM, 10 nM, 20 nM, 40 nM, 80 nM, and 160 nM
Exposure duration
incubation at room temperature for 30 min
Vehicle
inhibitor solubilized in 100% DMSO
Reported limits
Not stated in the sentences used: route, control.
Methods and source locations

Compound reported in the paper: MLN8054

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

2. Results > 2.2. PHA-680626 and RPM1722 Behave as CD Inhibitors In Vitro (S12); 4. Materials and Methods > 4.4. Kinase Activity Assays (S85, S86, S87, S88, S89, S90); Table 1 (T1.h1, T1.r2)

kinase activity of AURKA: kinase activity of AURKA — 4. Materials and Methods > 4.4. Kinase Activity Assays (S90); Table 1 (T1.h1, T1.r2)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 869363-13-3
Applications Aurora A Inhibitor
Formula C25H15ClF2N4O2
Molecular Weight 476.9
SMILES
C1C2=CN=C(N=C2C3=C(C=C(C=C3)Cl)C(=N1)C4=C(C=CC=C4F)F)NC5=CC=C(C=C5)C(=O)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 91 mg/mL (190.82 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
28 mg/mL
Vehicle
15% Captisol

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

MLN8054 Research References

  1. [1] Boi D, Souvalidou F, Capelli D, et al. PHA-680626 Is an Effective Inhibitor of the Interaction between Aurora-A and N-Myc. Int J Mol Sci (2021). PMID: 34884931 DOI: 10.3390/ijms222313122 Source material
  2. [2] Mahdipour M, Leitoguinho AR, Zacarias Silva RA, et al. TACC3 Is Important for Correct Progression of Meiosis in Bovine Oocytes. PLoS One (2015). PMID: 26168150 DOI: 10.1371/journal.pone.0132591 Source material
  3. [3] DeLuca KF, Meppelink A, Broad AJ, et al. Aurora A kinase phosphorylates Hec1 to regulate metaphase kinetochore-microtubule dynamics. J Cell Biol (2018). PMID: 29187526 DOI: 10.1083/jcb.201707160 Source material

Added to your cart

View Cart Checkout
Loading...